Prognosis of pregnancies in women with antiphospholipid syndrome has dramatically improved over the past two decades using conventional treatment with low molecular weight heparin and low-dose aspirin. However, despite this regimen, 10-15% of antiphospholipid syndrome patients experience pregnancy losses. Several studies have been performed in order to identify risk factors predictive of complications. Thrombosis has been generally accepted as the key pathogenetic mechanism underlying pregnancy morbidity. However, the thrombogenic state alone is not able to explain all the different mechanisms leading to pregnancy failure. In fact, emerging evidence shows that complement pathway could play an important role in mediating clinical events in antiphospholipid syndrome. However, the exact mechanism through which complement mediates antiphospholipid syndrome complications remains unknown.
Introduction
Antiphospholipid syndrome (APS) is an acquired thrombophilic disease, diagnosed by the persistent presence of antiphospholipid antibodies (aPL) such as lupus anticoagulant (LA), anticardiolipin antibodies (aCL) and anti-beta 2 GP1 (anti-b2GP1) in patients with vascular thrombosis and/or pregnancy morbidity. Thrombotic events include arterial and venous thrombosis, both in large or small vessels, confirmed by imaging or histopathology in the absence of significant evidence of inflammation in the vessel wall. Adverse obstetric outcome includes: three or more consecutive spontaneous miscarriages before week 10 of gestation, and/or one or more unexplained fetal death at or beyond week 10 of gestation, and/or one or more preterm delivery at/or before week 34 of pregnancy due to severe preeclampsia, HELLP syndrome (hemolytic anemia, elevated liver enzymes, low platelet count) or placental insufficiency. 1 Prognosis of pregnancies in women with APS has dramatically improved over the past two decades, using conventional treatment based on heparin and low-dose aspirin (LDA). Several studies have been performed in order to identify risk factors predictive of complications despite the conventional treatment. [2] [3] [4] [5] However, despite this regimen, 10-15% of APS patients experience pregnancy losses and could be defined as refractory obstetrical APS. [6] [7] [8] [9] [10] events through two possible ways: by a direct effect on platelets, endothelial cells, monocytes and throphoblastic cells and by an indirect interaction with components of the coagulation cascade and fibrinolytic proteins.
Among the different pathogenic mechanisms involved in explaining maternal and fetal complications of APS pregnancies, intraplacental thrombosis was traditionally suggested to be the main pathogenic event. It is well established in literature that aPL could induce a general procoagulant state, characterized by endothelial cell activation, inhibition of the protein C/S system, increased thromboxane synthesis, tissue factor activation and cytokine production. 11, 12 Moreover, some studies demonstrated that aPL could cause placental damage by interference with the activity of annexin. 13 The syncytiotrophoblast, in fact, naturally exteriorizes phosphatidylserine, a trigger of contact-dependent coagulation. In normal pregnancies, exteriorized phosphatidylserine may be protected from maternal coagulation factors by annexin V, a phosphatidylserine-binding protein that is thought to form a lattice-like shield over the surface of the syncytiotrophoblast. In pregnancies complicated by APS, it has been demonstrated that aPL could displace annexin V from the surface of placental explants or syncytialized trophoblasts, as suggested by experiments performed in vitro. 14, 15 De Wolf et al. first published histological reports of placental tissues from pregnancies complicated by APS, finding that intraluminal thrombosis could be detected in 50% of these placentae. 16 This hypothesis was subsequently supported by other histological findings of intervillous thrombosis, extensive villous fibrosis or marked infarction. More recently it was observed that in the placentae of women with APS not only placental infarctions can be detected but also increased syncytial knots, decreased vasculosyncytial membranes, decidual inflammation and impaired spiral artery remodelling. 17 These different types of lesions suggest that multiple pathological events may occur in pregnancies complicated by APS and the thrombogenic state alone is not able to explain all the different mechanisms leading to pregnancy failure. Some in vitro studies demonstrated that aPL adversely affect trophoblast functions, impairing their invasion, differentiation and maturation, through mechanisms unrelated to thrombosis. 18, 19 If an abnormal early trophoblast invasion is the candidate mechanism able to explain the first trimester pregnancy losses, on the other hand, second-and third-trimester fetal losses are more likely to be the results of a thrombotic damage on the uteroplacental vasculature. Moreover, the oxidative stress, by aPL cross-reaction with oxidized LDL (Low Density Lipoproteins), and the aPL mediated complement activation can be considered contributing factors in placental injury, suggesting an autoimmune inflammatory role in aPL-related obstetrical complications. 20, 21 Other mechanisms were also involved in aPL-associated defective placentation, such as direct cellular injury, apoptosis, inhibition of proliferation and syncytia formation, decreased GnRH-induced human chorionic gonadotrophin (hCG) production and impaired invasiveness. 22, 23 The evidence that thrombosis cannot completely explain APS clinical manifestations has shifted the focus of research to other pathogenetic mechanisms, such as inflammation.
In fact, in pregnancy, the maternal immune responses undergo many changes to allow for normal implantation and development of the fetus. An imbalance towards pro-inflammatory mediators (complement, TNF and chemokines) has been linked to aPL induced fetal loss in animal models. 24 Following fetal resorption due to injection of IgG with aPL-activity to pregnant naı¨ve mice, histological examination of the decidua revealed deposition of human IgG with mouse complement, neutrophil infiltration and local TNF secretion.
Complement pathway
Emerging evidence shows that complement pathway could play an important role in mediating clinical events in APS. The complement pathway is a strategic component of immune systems in close collaboration with other components of innate and adaptive immunity. It acts as an efficient surveillance system discriminating between healthy host tissue, cellular debris, apoptotic cells and microbial cells.
The complement consists of more than 20 plasma and membrane proteins circulating as inactive enzyme precursors. The activation of one component triggers a stepwise cascade that results in the deposition of complement fragments on pathologic targets and the release of fragments that promote inflammation. 25 Three different activation pathways of the complement system have been described, according to the difference in activation elements involved. The classical pathway starts with the binding of immunoglobulin IgM or IgG to an antigenic target (bacterial, viral or autoantigen); the Fc portion of the antibody is then bound by the C1q subcomponent of the C1 complex and this event causes the cleavage of C1 by autoactivation, leading to C1r formation. Activated C1r then cleaves and activates C1s, which in turn cleaves C4 and C2. Resultant fragments C4b and C2a form the C3 convertase C4b2a. The lectin pathway is activated by the binding of a mannose-binding lectin to repetitive sugar sequences on the pathogen's surface. Notably, lectins do not bind sugar found on mammalian cell-surface glycoproteins and, thus, distinguish pathogen surfaces from host cellular surfaces. After this binding, MASP (Mannose-Associated Serine Protease) cleaves C4 and C2, releasing C4b and C2a to form the C3 convertase C4bC2a. The alternative pathway is capable of recognizing and destroying foreign pathogens in the absence of antibody binding. It is initiated by the low rate of spontaneous hydrolysis of C3 ('C3 tick-over'), which is abundant in the blood plasma. Hydrolyzed C3 binds the plasma protein factor B, which allows factor D to cleave factor B into Ba and Bb. C3bBb is the C3 convertase of the alternative pathway and is stabilized by properdin, forming C3bBbP, which cleaves C3 to deposit C3b on the target surface. Some C3b also forms the C5 convertase C3bBC3bP. These three pathways converge in the formation of a C3 convertase that activates C3, forming the C3b fragment. The following step is the activation of C5 by a C5 convertase; the C5b fragment then forms a multimolecular unit consisting of C5b, C6, C7, C8 and C9, known as the membrane attack complex (MAC). The MAC forms transmembrane channels in targeted cells that result in cell membrane disturbance and ultimately cell lysis. Activation of the complement components also leads to the production of C3a and C5a, called 'anaphilatoxins'; these are strong proinflammatory molecules that recruit inflammatory cells, such as neutrophils and monocytes.
Other complement proteins, such as DAF, CD59, MCP, CFI and CFH, work as regulatory or control proteins to prevent complement damage to normal host tissues. 26 The placenta represents an important site of complement system function. The complement protects the fetal-maternal interface against invading pathogens and promotes the removal of immune complex and apoptotic cells. 27 
Complement activation in APS pregnancy
The crucial role of complement involvement in inducing aPL-mediated fetal loss is supported by several lines of evidence. 28 However, the exact mechanism through which complement mediates APS complications remains unknown.
In animal models, Pierangeli et al. 29 have shown that inhibition of the complement cascade in vivo, using C3 convertase inhibitor, blocks aPL-induced fetal loss and growth retardation and inhibits aPL-mediated thrombosis. Mice deficient in complement C3 and C5 showed resistance to thrombosis, endothelial cell activation and fetal loss. Hence, complement activation may be a critical phase in the pathogenesis of thrombosis and fetal loss associated with aPL. 29, 30 Factor H, a complement inhibitor, has structural similarities to b2-GP1. A significant increase in levels and frequencies of Factor H autoantibodies was found in cohorts of patients with APS compared with matched healthy controls, in both primary antiphospholipid syndrome (PAPS) and secondary antiphospholipid syndrome (SAPS). Factor H interacts with various types of cells, particularly when these are damaged or contain deposits of C3b resulting from activation of the complement cascade. 31 Moreover, in the placentas of APS patients, there was increased deposition of complement products C4d and C3b, compared with normal subjects. 32 Mild hypocomplementemia and low C3, C4 levels were reported in some studies including patients with APS with no other associated systemic autoimmune diseases. [33] [34] [35] Lower C3 and C4 levels at the baseline and at the end of pregnancy have been reported to significantly correlate with poor pregnancy outcome. 34 Moreover, increased plasma levels of the activation products Bb and C5b-9 have been reported in women with aPL and adverse pregnancy outcomes (APOs). Activation products are considered to be a more sensitive marker of complement activation and may promote leukocyte recruitment/activation and the release of proinflammatory and anti-angiogenic mediators responsible for placental damage. 36 It has also been reported that aPL, by activation of toll-like receptor 4 (TLR4), induce uric acid production in response to human trophoblast, which in turn, activates the Nalp3/ASC (apoptosisassociated speck-like protein) inflammasome complex, leading to IL-1b and IL-8 secretion with a strong inflammatory response. 37 The anti-inflammatory cytokine IL-3 is important for the maintenance of normal pregnancy. IL-3 enhances placental and fetal development while increasing the number of megakaryocytes. The serum level of IL-3 in pregnant patients with Complementemia in pregnancies with APS S Tabacco et al.
PAPS or APS secondary to Systemic Lupus
Erythematosus (SLE) has been found to be lower than in controls. In vitro studies revealed that low dose-aspirin stimulates IL-3 production. 38 Other cytokines may be involved in the aetiology of APS. The level of the proinflammatory and prothrombotic cytokine TNF-a was shown to be significantly higher in patients with APS than healthy controls. This mediator links complement C5a-C5aR interactions and pathogenic aPL to fetal damage. 39 The aPL that target decidual tissue could cause a rapid increase in decidual and systemic TNF levels. Studies on mice suggested that miscarriages induced by aPL are less frequent in those who are deficient in TNF or treated with TNF blockade. In humans, TNF contributes to the pathogenesis of poor pregnancy outcomes: TNF-a increases throughout pregnancy and has been related to miscarriages, fetal losses, PE and preterm birth as well as IL-10 reduction. 40 Trophoblast cells express the surface antigen CD1d, bearing phosphatidylserine (PS). Anti-b2GPI antibodies have been shown to interact with the PS-bearing CD1d, causing release of IL12 and induction of IFNa production, thus supplying additional evidence that APS-related pregnancy loss involves an inflammatory mechanism. 41 Recently, the role of anti-C1q antibodies in complement activation has been investigated both in APS patients and in unexplained recurrent pregnancy loss. Oku et al. 42 firstly highlighted the association of anti-C1q antibodies with complement activation in 40 consecutive primary APS. The presence of these antibodies contributed to manifestation of APS, especially in refractory cases, suggesting a pathogenic mechanism for APS manifestation other than the presence of circulating aPLs. Another recent study revealed also an association between the prevalence of anti-C1q and unexplained recurrent pregnancy loss. 43 The mechanism of anti-C1q antibodies in APS pathophysiology might possibly lead to a new therapeutic approach and understanding of the disease.
Predictive value of hypocomplementemia
The placenta normally provides a stimulating substrate for complement activation. In fact, fetal tissue is in direct contact with maternal blood on the trophoblastic surface where the exposition to paternal antigens can induce complement activation. 42 Even when there is deposition of complement components in the chorionic villi and basal membranes, under normal circumstances, this tissue is not damaged by complement, 43 probably because of the presence of complement regulatory proteins such as DAF, MCP, and CD59, which are expressed highly by cytotrophoblasts and syncytiotrophoblasts. In contrast, placentas from APS patients showed an extensive deposition of complement activation products with large tissue damage, suggesting that the protection by complement regulatory proteins is not enough to oppose the aPL exposure. Outside pregnancy, hypocomplementemia has been found in a significant proportion of patients with PAPS and was associated with thrombosis, livedo reticularis and thrombocytopenia. 44 In order to investigate the predictive value of complement components (serum C3 and C4) in pregnancies with APS, a prospective study was performed in our centre. 45 Pregnancy outcome was analyzed in terms of the following features: fetal loss, preterm delivery (<34 gestational weeks), intra-uterine growth restriction (IUGR), birth weight <2500 g, preeclampsia, week at delivery, birth weight and birth weight percentile. Hypocomplementemia and triple aPL positivity were related to pregnancy outcome. Fetal death, preterm delivery and birth weight <2500 g were associated with hypocomplementemia (p ¼ 0.019, p ¼ 0.0002, p < 0.0001, respectively). Lower birth weight, lower birth weight percentile and lower week at delivery were associated with hypocomplementemia (p < 0.0001, p ¼ 0.0003, p < 0.0001, respectively) and with triple aPL-positivity (p ¼ 0.008, p ¼ 0.014, p ¼ 0.03, respectively). Therefore, hypocomplementemia was associated with poor pregnancy outcome in PAPS pregnancies. Using multivariate analysis, hypocomplementemia was an independent predictor of lower birth weight (p ¼ 0.0001) and lower week at delivery (p ¼ 0.002).
Other investigators 46 evaluated the association between serum complement levels (C3 and C4) and obstetric complications in pregnancies complicated with PAPS: pregnancies in PAPS were compared with a group of healthy women. The PAPS group showed significantly lower levels of C3 and C4 in each trimester in comparison with healthy women, but no association was found between hypocomplementemia and the obstetric complications investigated in this study.
In the European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS), the complement pathway in 201 women with obstetric APS was analyzed: 49% women showed decreased values of complementemia, such as low C4 levels or low C3 levels or low C4 and C3 levels. 33 Ruffatti et al. compared APS patients with successful and unsuccessful pregnancy outcome: 410 pregnancies of women with PAPS were considered. The study focused on 57 unsuccessful pregnancies (considered the study population) and 57 successful pregnancies (considered the control population) matched for age and therapy. Lower C3 and C4 levels at baseline and at the end of pregnancy were both found to be significantly correlated with poor pregnancy outcome (p ¼ 0.004 and p ¼ 0.046, respectively). 34 More recently, Deguchi et al. confirmed that low complements were associated with APOs. 35 A recent study by Kim et al. 47 reported that complement activation could also be a predictor of adverse pregnancy outcome. In the PROMISSE study (Predictors of pRegnancy Outcome: bioMarkers
In antiphospholipid antibody Syndrome and Systemic Lupus Erythematosus), 487 pregnant women with SLE and/or aPL were enrolled. Complement activation products (Bb and sC5b-9) were measured on serial blood samples obtained at each monthly visit. APOs included one or more of: (1) fetal death after 12 weeks' gestation unexplained by chromosomal abnormalities, anatomical malformation or congenital infection; (2) neonatal death before hospital discharge due to complications of prematurity and/or placental insufficiency; (3) indicated preterm delivery at less than 36 weeks due to gestational hypertension, preeclampsia or placental insufficiency; and (4) smallfor-gestational-age (SGA) neonate (<5th percentile). The results showed that in pregnant SLE and/or aPL patients, increased Bb and sC5b-9 detectable early in pregnancy is strongly predictive of APOs and supports activation of complement, particularly the alternative pathway, as a contributor to APOs. In particular, when analyses were restricted to patients with aPL (n ¼ 161), associations between Bb at 12-15 weeks and APOs became stronger.
Association between complement tests and pregnancy outcomes is shown in Table 1 .
In our opinion, all these data [33] [34] [35] [45] [46] [47] suggest that hypocomplementemia could be considered as a prognostic factor for poor pregnancy outcome in APS patients. In presence of hypocomplementemia, a more careful monitoring of maternal and fetal wellbeing is indicated throughout pregnancy. Thus, low levels of circulating complement components could be used to identify APS pregnancies at higher risk of obstetric complications; on the other hand, a normal complementemia could be a useful tool for reassuring counselling, either at preconception or at the beginnings of pregnancy. In conclusion, hypocomplementemia could be an early predictor of APO, available at the beginning of pregnancy for adding, if necessary, any treatment to conventional therapy. 48 However future studies need to better understand the impact of low complement level on APS pregnancy outcome. 
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